Janssen Pharmaceutica NV has identified 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, viral hepatitis, diabetes, immunological, inflammatory, neurological, cardiovascular and metabolic disorders.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Chengdu Baiyu Pharmaceutical Co. Ltd. has disclosed NLRP3 inflammasome inhibitors acting as pyroptosis inhibitors reported to be useful for the treatment of gout, Alzheimer's disease, atherosclerosis, diabetes, psoriasis, rheumatoid arthritis, graft-vs.-host disease and familial cold urticaria syndrome.
Chengdu Baiyu Pharmaceutical Co. Ltd. has synthesized NLRP3 inflammasome inhibitors acting as pyroptosis inhibitors reported to be useful for the treatment of cancer, autoimmune, cardiovascular, endocrine, respiratory, renal, neurological and gastrointestinal disorders, among others.
Scientists at the University of Turin and the University of Pisa have identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation, neurodegeneration, cancer, cardiovascular disorders, and autoimmune and metabolic disease.
Janssen Pharmaceutica NV has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of osteoarthritis, cancer, nonalcoholic steatohepatitis (NASH), skin lesion, sarcoidosis, as well as cardiovascular, metabolic and Alzheimer's diseases, among others.
Kotobuki Pharmaceutical Co. Ltd. and Astellas Pharma Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration and inflammatory disorders.
Bioage Labs Inc. has synthesized new NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndromes, hearing loss, Ménière's disease, tinnitus, vertigo and inflammatory disorders.
After two years of talks, privately held Ventus Therapeutics Inc. and Novo Nordisk A/S have signed an exclusive worldwide license deal to commercialize candidates from Ventus’ portfolio of peripherally restricted NLR pyrin domain-containing 3 (NLRP3) inhibitors. Along with Roche Holding AG’s September 2020 acquisition of Inflazome Ltd. and Novartis AG’s buyout of subsidiary IFM Tre in April 2019, this is another step by big players to get into the NLRP3 space.
